

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Yestar Healthcare Holdings Company Limited

巨星醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2393)

ANNOUNCEMENT POSITIVE PROFIT ALERT

This announcement is made by Yestar Healthcare Holdings Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company hereby informs the shareholders and potential investors of the Company that, based on the currently available unaudited management accounts of the Group and the preliminary assessment by the Company’s management, the Group is expected to record an unaudited consolidated net profit of the Group of not less than RMB11.6 million and an unaudited consolidated net profit attributable to the owners of the parent of not less than RMB3.6 million for the six months ended 30 June 2023 (the “**Interim Period 2023**”) as compared to an unaudited consolidated net loss of the Group of approximately RMB184.1 million and an unaudited consolidated net loss attributable to the owners of the parent of approximately RMB165.3 million for the six months ended 30 June 2022.

The expected turnaround from net loss to net profit of the Group for the Interim Period 2023 are primarily attributed to the following:

1. An overall increase in revenue of our medical business and non-medical business, which was due to a rebound in the demand on all our products resulted from the general recovery of medical industry and economy in the PRC.
2. A slight increase in gross profit margin of our products due to an increase in demand.

3. An absence of any significant impairment loss on inventories, financial assets, goodwill and other intangible assets of the Group for the Interim Period 2023.

The Group is still in the process of finalizing its unaudited consolidated results for the Interim Period 2023. The information contained in this announcement is only a preliminary assessment by the Board based on the unaudited management accounts for the Interim Period 2023 and the information currently available to the Board, which may be subject to further adjustments after further internal review by the Board. Details of the unaudited financial performance of the Group will be contained in the interim results announcement of the Group for the Interim Period 2023, which is expected to be published on 25 August 2023.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Yestar Healthcare Holdings Company Limited
Liao Changxiang
Executive Director and Chief Executive Officer

16 August 2023

As at the date of this announcement, the executive Directors are Ms. Liao Changxiang, Ms. Wang Hong and Mr. Liang Junxiong; the non-executive Director is Mr. Hartono James; and the independent non-executive Directors are Mr. Zeng Jinsong, Mr. Zhao Ziwei and Koeswondo Michael David.